Xcell Therapeutics Inc. (KOSDAQ:373110)

Market Cap	21.25B -49.4%
Revenue (ttm)	1.95B +0.8%
Net Income	-10.93B
EPS	-938.00
Shares Out	17.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	382,338
Average Volume	213,377
Open	1,335.00
Previous Close	1,229.00
Day's Range	1,305.00 - 1,597.00
52-Week Range	1,212.00 - 4,120.00
Beta	n/a
RSI	27.10
Earnings Date	Apr 13, 2026

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 373110

Financial Performance

In 2025, Xcell Therapeutics's revenue was 1.95 billion, an increase of 0.76% compared to the previous year's 1.93 billion. Losses were -10.93 billion, 14.5% more than in 2024.